perindopril has been researched along with Local Neoplasm Recurrence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimoto, M; Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Mitoro, A; Noguchi, R; Sawai, M; Toyohara, M; Tsujimoto, T; Uemura, M; Yamao, J; Yamazaki, M; Yoshida, M; Yoshiji, H | 1 |
| Aihara, Y; Fujimoto, M; Fukui, H; Ikenaka, Y; Kaji, K; Mitoro, A; Morioka, C; Noguchi, R; Sawai, M; Toyohara, M; Uemura, M; Yamao, J; Yamazaki, M; Yoshida, M; Yoshiji, H | 1 |
2 trial(s) available for perindopril and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Hepatocellular; Catheter Ablation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Perindopril; Survival Rate; Vascular Endothelial Growth Factor A; Vitamin K 2 | 2009 |
Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial.
Topics: Aged; Amino Acids, Branched-Chain; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Insulin Resistance; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Perindopril; Treatment Outcome | 2011 |